Sanofi begins three-year immunology R&D tie-up with StanfordSanofi has begun a three-year research collaboration with Stanford University School of Medicine, working on better understanding of Share XSanofi begins three-year immunology R&D tie-up with Stanfordhttps://pharmaphorum.com/news/sanofi-begins-three-year-immunology-rd-tie-up-with-stanford-university/
New CEO Mortazavi takes UK biotech e-therapeutics into gene silencingUK biotech e-therapeutics has a new CEO, with executive chairman and former Silence Therapeutics chief Ali Mortazavi chosen Share XNew CEO Mortazavi takes UK biotech e-therapeutics into gene silencinghttps://pharmaphorum.com/news/new-ceo-mortazavi-takes-e-therapeutics-into-gene-silencing/
Roche bulks up in inflammation with €380m Inflazome acquisitionRoche has made a second acquisition in the area of NLRP3 inhibitors for inflammatory diseases, buying Irish biotech Share XRoche bulks up in inflammation with €380m Inflazome acquisitionhttps://pharmaphorum.com/news/roche-bulks-up-in-inflammation-with-e380m-inflazome-acquisition/
IL-6 hypothesis looking shaky as Kevzara fails COVID-19 trialHopes that already-approved drugs targeting IL-6 could be repurposed to treat COVID-19 have been undermined by disappointing results Share XIL-6 hypothesis looking shaky as Kevzara fails COVID-19 trialhttps://pharmaphorum.com/news/il-6-hypothesis-looking-shaky-as-kevzara-fails-covid-19-trial/
FDA clears emergency use of Roche test for COVID-19 ‘cytokine storm’Roche has been given a green light by the FDA to use one of its diagnostic tests to Share XFDA clears emergency use of Roche test for COVID-19 ‘cytokine storm’https://pharmaphorum.com/news/fda-clears-emergency-use-of-roche-test-for-covid-19-cytokine-storm/
Innovating in inflammation and immunologyFor World Inflammatory Bowel Disease day we spoke to Pfizer’s Matt Shaulis, president of international developed markets for Share XInnovating in inflammation and immunologyhttps://pharmaphorum.com/r-d/views-analysis-r-d/innovating-in-inflammation-and-immunology/
Verona says FDA backs plan to take COPD drug into phase 3More than two years after first saying it would take its lead drug into a pivotal trial, Verona Share XVerona says FDA backs plan to take COPD drug into phase 3https://pharmaphorum.com/news/verona-says-fda-backs-plan-to-take-copd-drug-into-phase-3/
Blockbusters in waiting: drug launches to watch in 2020New drugs for breast cancer, lymphoma, multiple sclerosis and migraine are among new product launches this year that Share XBlockbusters in waiting: drug launches to watch in 2020https://pharmaphorum.com/news/blockbusters-in-waiting-drug-launches-to-watch-in-2020/
BMS, BioMotiv alliance generates biopharma company AnterosA partnership between Bristol-Myers Squibb and drug development accelerator BioMotiv has yielded its first fruit just a few Share XBMS, BioMotiv alliance generates biopharma company Anteroshttps://pharmaphorum.com/news/bms-biomotiv-alliance-generates-biopharma-company-anteros/
